Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair (EVAR_DAPT_SAPT)
A Target Trial Emulation for Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients who underwent EVAR for AAA and were successfully discharged
Exclusion Criteria:
- Patients who had experienced a myocardial infarction
- Patients who had experienced a stroke
- Patients who had experienced percutaneous coronary intervention
- Patients who had history of peripheral disease
- Patients who had major bleeding event within 1 year of admission
- Those prescribed non-vitamin K antagonist oral anticoagulant or warfarin
- Patients who did not prescribe any antiplatelet therapy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Dual antiplatelet therapy
Patients who were prescribed dual antiplatelet therapy at the date of discharge from the index hospitalization for standard EVAR
|
|
Single antiplatelet therapy
Patients who were prescribed single antiplatelet therapy at the date of discharge from the index hospitalization for standard EVAR
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major adverse cardiac and cerebrovascular events (MACCE)
Time Frame: 1 year after EVAR
|
composite of all-cause death, myocardial infarction (MI), or ischemic stroke
|
1 year after EVAR
|
|
Major or clinically relevant non-major bleeding
Time Frame: 1 year after EVAR
|
Diagnostic codes in the primary or secondary position and transfusion receipt
|
1 year after EVAR
|
|
Re-intervention or surgery for AAAs
Time Frame: 1 year after EVAR
|
Re-intervention or surgery for AAAs
|
1 year after EVAR
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Antiplatelet After EVAR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.